

The Max Perutz Fund

(A company limited by guarantee)

ANNUAL REPORT AND FINANCIAL STATEMENTS

For the year ending 30 September 2023

Charity Commission number 1129597

Company number 06876186

The Max Perutz Fund (a company limited by guarantee)

Contents	Page Numbers
Legal and administrative information	2
Report of the Trustees	3 - 10
Report of the Auditors	11 - 13
Statement of financial activities	14
Charity balance sheet	15
Notes forming part of the financial statements	16 - 25

The Max Perutz Fund (a company limited by guarantee)

Legal and administrative information

Charity registration number: 1129597

Company registration number: 6876186

Directors and

Trustees:

Dr Kevin Moreton	24/11/15 – present
Dr Jan Löwe	17/05/18 – present
Dr Liz Miller	13/08/18 – present
Dr Leo James	28/03/19 – present
Dr Anne Bertolotti	05/11/20 – present

Secretary:

Mrs Josie Gowler FCA 18/04/18 – present

Registered Office:

MRC Laboratory of Molecular Biology
Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0QH

Auditors:

Price Bailey LLP:
Tennyson House
Cambridge Business Park
Cambridge
CB4 0WZ

Bankers:

Lloyds Bank PLC:
3 Sidney Street
Cambridge
CB2 3BU

Solicitors:

HCR Legal LLP:
50-60 Station Road
Cambridge
CB1 2JH

The Max Perutz Fund (a company limited by guarantee)

Report of the Trustees (incorporating a Directors' Report) for the year ended 30 September 2023

The Trustees, who are also directors of the charity for the purposes of the Companies Act, submit their annual report and the audited financial statements for the year ended 30th September 2023. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the charity.

The charity is a charitable company limited by guarantee and was set up on 14th April 2009. It is governed by a memorandum and articles of association. Its objects are the promotion and advancement of education and research in molecular science and allied biomedical fields including by the award of prizes for scientific achievement or potential.

Structure, governance and management

The Max Perutz Fund was established as a charitable company in April 2009, to replace the previous charity of the same name, which was an unincorporated charity (Charity Commission number 280871). This had been established in 1980 to mark the retirement of Dr Max Perutz as the first chairman of the MRC Laboratory of Molecular Biology. The previous charity was subsequently merged into the new charity with effect from 2 December 2010, the funds having transferred in January 2010.

The charity is closely associated with the MRC Laboratory of Molecular Biology (LMB), and the articles make specific provision for the Director of the LMB to be a Trustee, if he/she so wishes. Dr Jan Löwe, currently Director of the LMB, is chairman of the Trustees.

The Trustees are the members of the charity, and new Trustees are appointed by the current Trustees in line with the articles. It is the Trustees' intention that they should represent a range of scientific expertise.

Mrs Josie Gowler, the LMB's Head of Finance and Research Contracts, acts as company secretary, without remuneration from the charity.

The Trustees ensure they comply with the Charity Governance Code for smaller charities as follows:

- **Organisational purpose:** the Trustees are clear about the charity's aims and ensure that these are being delivered effectively and sustainably via board meetings and informal discussions between meetings. Further information is shown in the section 'Objectives and Public Benefit' below.
- **Leadership:** Dr Jan Löwe, currently Director of the LMB, is chairman of the Trustees and the board leads the achievement of the charity's aims and values.
- **Integrity:** Trustees act with integrity at all times, as monitored at board meetings. Further information on managing potential conflicts of interest is detailed on page 4.
- **Decision-making, risk and control:** the Trustees make all the decisions in respect of the charitable company, which does not have any employees. The Trustees meet formally at least twice a year to agree strategy and areas of activity for the Fund, including the awards of grants and prizes, together with decisions on investments, reserves and risk management; informal discussions take place as necessary between the formal meetings.
- **Board effectiveness and diversity:** Board effectiveness is kept under review as part of the meetings of the Trustees and appointments ensure that the Board has an appropriate balance of skills, experience, backgrounds and knowledge to make informed decisions.
- **Openness and accountability:** the charity is open in its work, which is publicised through its website and at LMB open days.

Training

All new Trustees are provided with copies of guidance produced by the Charity Commission and of the charity's key documents. These documents, as well as the memorandum and articles of the company, are filed on a shared server along with further information prepared by the company secretary, so that all Trustees can access the

The Max Perutz Fund (a company limited by guarantee)

guidance easily. An annual discussion session on Trustee responsibilities and on changes to legislation is provided by the Fund's legal advisors.

Risk Management

The Trustees have considered the major risks to which the charity is exposed, keep these risks under review, and have established systems and procedures to manage these risks. The risk register is reviewed and updated at the Trustees' meetings twice per year.

Conflicts of interest

The Trustees have established a policy on conflicts of interest and a register of interests. The policy explicitly addresses the handling of financial relationships with the MRC Laboratory of Molecular Biology, since five of the Trustees are also employees of the Medical Research Council, which is part of UK Research and Innovation (UKRI).

Public benefit statement

The Trustees confirm that, to the best of their knowledge and ability, they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties. The report below gives more details about the specific public benefit from the use of the Max Perutz Fund's charitable funds.

Objectives and public benefit

The objectives of the charity are the promotion and advancement of education and research in molecular biology and allied biomedical sciences including by the award of prizes for scientific achievement or potential.

The principal activities in support of these objectives are the funding of research, which delivers public benefit through adding to our understanding of the biological processes at the molecular and cellular level and therefore has the potential to help tackle problems in human health and disease. While it is not possible to predict with certainty the outcome of any particular research project, it is the expectation of the Trustees that all the research funded by the charity will lead to publications in the scientific literature. In this way the results of the research are publicly available, and can be freely used by scientists internationally in other research projects. It can be very difficult to track the contributions of an individual research result to a new drug or diagnostic method, but the basic research supported by the Fund is an essential building block for future improvements in health care, to the benefit of the public worldwide.

The Max Perutz Fund supports young scientists to travel to international conferences, to publicise their work, and to benefit from discussions with other scientists to help foster and enhance their research activities.

Lectures arranged by the Max Perutz Fund are open to the public and are advertised on the internet so they are fully accessible.

The Max Perutz Fund also awards prizes in October each year to:

- PhD students in the MRC Laboratory of Molecular Biology who have made significant contributions to research during their studies. These prizes encourage and reward excellence in research, and prize winners are expected to have produced at least one publication, which is a measure of the success of the research project, as well as ensuring wider visibility of the research results.
- Outstanding postdoctoral researchers who have been in post for less than six years.
- Technical and support staff who have made an exceptional contribution to the LMB – this prize was awarded for the first time in October 2022.

The Max Perutz Fund is a single charity encompassing separate funds reflecting the aims of the original donors.

The Perutz Fund (designated) is used to fund prizes to young scientists and other approved purposes.

The Max Perutz Fund (a company limited by guarantee)

The Milstein Fund (designated) funds a studentship or fellowship to enable a young scientist from South America to undertake research at the LMB.

The AstraZeneca Lecture Series (designated) provides a forum where lectures are given by top researchers in biological and medical studies to an interested open public audience.

The Michael Neuberger Studentship (designated) funds PhD studentships for training in fundamental biological and medical research.

The Brenner Postdoc Prize (restricted), sponsored by Royalty Pharma, is a restricted fund for prizes for exceptional postdocs. It has subsequently been renamed the Steitz Postdoc Prize.

The Sangamo Aaron Klug Symposium Fund (restricted) was created through a donation from Sangamo Therapeutics Inc to support the Aaron Klug Symposium which celebrated the life and impact of Aaron Klug. Post-symposium, the remaining funds will be used for academic support.

The Grigg Fellowship Fund (expendable endowment) is to promote closer links between the Garvan Institute of Medical Research in Australia and the LMB.

The Graduate Scientist/Postdoctoral Researcher Fund ('GSA/PAL') (restricted) was created in 2022 and is used to fund networking activities for graduate students and postdoctoral researchers.

Two Funds within the charity are to support the work of Dr Venkatraman (Venki) Ramakrishnan. The first is a restricted donation from the Louis Jeantet Foundation in respect of his award of the Louis Jeantet Prize in 2007. Dr Ramakrishnan's work on the atomic structure and workings of the ribosome, which is responsible for protein synthesis within cells, has the potential to underpin the development of new drugs to help fight antibiotic resistance. The second fund, in the form of an expendable endowment, is from the Agouron Institute.

The Louis Jeantet Prize awarded to Dr Gregory Winter in 1989 was administered originally by the charitable funds of the MRC; in 2012 by mutual agreement it was transferred to the Max Perutz Fund. The fund was intended to be used to underwrite Dr Winter's research on Bicyclic Peptides. The scientific group carrying out this research was discontinued when Dr Winter took up the position of Master of Trinity College Cambridge. During 2015 Dr Winter agreed with the Max Perutz Fund Trustees to donate £150,000 from his Jeantet prize to contribute to the setting up of the Michael Neuberger Studentship at Trinity College Cambridge. On 6 January 2021, the Sir Gregory Winter Jeantet Prize Fund (charity registration no: 1129597-1) became a linked charity to The Max Perutz Fund. Further information on the transfer is disclosed in note 15 to the accounts.

Options continue to be investigated to use Dr Winter's Jeantet funding for opportunities in Synthetic Biology; a research area closely allied to Bicyclic Peptides, or more broadly in the area of Protein and Nucleic Acid Chemistry.

The Fidelity Bermuda Foundation awarded a grant to support a project of Ben Ryskeldi-Falcon at the LMB, entitled 'In situ structural cell biology of tau and TDP-43 filaments in the human brain'. The first year of funding was received and remitted to the LMB during the year.

The General Fund can be used to support any of the objectives of the Fund. The Monoclonal Anti-Bodies (MABs) Film forms part of the General Fund. The film is being produced to provide an educational resource to schools and universities explaining the story of how Monoclonal Antibodies were discovered, the research and personalities involved, their development and the importance of their modern day use in the fight against disease and illness.

The Max Perutz Fund (a company limited by guarantee)

Achievements

Student Prizes

Three Max Perutz Student Prizes were awarded in October 2022, as follows:

Sofia Lövestam – Sofia embarked fearlessly on the in vitro recreation of the Tau filaments that are found in the brain of humans with diverse neurodegenerative diseases. She tested myriads of conditions to reach this goal and transformed cryo-EM of the filaments into a high-throughput platform technology. Her work heralds the beginning of a new era, providing opportunities to study and interfere with this pathological process.

Stanislau Yatskevich – Stan used electron cryo-tomography to reveal the native structure of the gamma-TuRC complex, identifying new mechanisms that resolve long-standing questions of how microtubules are nucleated at the mitotic spindle. Stan also reconstituted and solved the structure of a kinetochore complex that revealed how the spindle connects to chromatin to drive chromosome segregation, illuminating two of the most important processes required for mitosis.

Niklas Freund – Niklas developed polymerases that act on non-native nucleotides. His work exploited steric differences in modified nucleotides to engineer enzymes that efficiently accommodate these distinct substrates. He went on to use in vitro evolution techniques that leverage his engineered enzymes to yield exciting new aptamers with unique ligands. His work holds tremendous potential for therapeutic benefit through in vitro evolution of new catalysts, ligands and aptamers.

Steitz (formerly known as Brenner) Prizes

Three Postdoc Prizes were awarded in October 2022, as follows:

George Ghanim – George has made significant contributions to the understanding of telomerase. He was instrumental in the high-resolution structure determination of human telomerase, providing beautiful mechanistic explanations for some of the secrets of this important enzyme. He then went on to overcome long-standing biochemical problems with the shelterin complex to investigate what makes telomeres stable in cells.

Sami Chaaban – Sami has pioneered approaches to visualise dynein motor complexes by cryo-EM when bound to microtubules. This work led to the discovery of the molecular logic of how adaptors are used to connect the motors to cargos, how different motors are connected and to a convincing explanation for the previous finding that dynein steps to the right on microtubules.

Yang Yang – Yang determined the cryo-EM structures of A β 42 and α -synuclein assemblies, the two most common assemblies in neurodegenerative diseases. The nature of the α -synuclein filaments is such that others had thought it was impossible to solve their structure. This work is poised to have an exceptional impact in the field of neurodegeneration and is now being used to address outstanding mechanistic questions.

Eileen Southgate Prizes

Jon Howe – As a member of the light microscopy facility, Jon has been instrumental in the contributions that the facility has made to research at the LMB. But beyond his scientific impact, Jon's outreach brings the LMB mentality of discovery to the broader community. For example, he designed cases that allowed our successful Microscopes 4 Schools program to be shipped to schools across the country. This innovation overcame limitations of COVID-related restrictions and allowed us to reach underprivileged communities outside our normal sphere.

Carolyn Karam – Carolyn is a breeding facility manager for Ares who has worked tirelessly over the last three years to ensure her staff and the wider team have been supported through difficult times. During lockdown Carolyn's leadership shone through and her caring approach got them through the very difficult jobs they had to do at the time to preserve the service. Carolyn's dedication to supporting staff has benefited many careers, and her commitment to LMB has been a shining example for others to follow.

The Max Perutz Fund (a company limited by guarantee)

Sew-Yeu Peak-Chew – Sew-Yeu's mass spectrometry work has contributed to a large number of proteomic discovery projects. Because she goes above and beyond to help develop methods tailored to specific questions, the data she generates is of such quality that her work often provides direct answers to complex biological questions.

Freda Chapman – Freda works in Domestic Services and not only does she do an excellent job, she personifies what is best about LMB. She is a very generous and warm person who always greets everyone with a smile and goes out of her way to care for people. Freda makes a very important contribution to life and culture at the LMB.

Milstein Fellowship

The current Milstein Fellow, Dr Viviane de Souza Rosa, started her Fellowship in May 2021. She did her PhD in Brazil followed by a ten-month working visit to Cambridge during which time she achieved a co-first author publication working on the mechanisms of size regulation in the mouse embryo. She also contributed quite substantially to the project of another PhD student focused on the derivation of a new human stem cell line and is a second author in the manuscript that describes this work. Finally, she helped to set up the conditions to establish a 3D culture of embryonic stem cells. She is continuing with this work at the LMB. Her Fellowship has been extended to December 2024 to enable her to continue her work on mastering the generation of embryo chimeras and performing bioinformatic analyses of sequencing data using Python.

AstraZeneca Lecture Series

The purpose of the lecture series is for international and national experts in the field of biological and medical research to present their current research. Lectures are open to anyone who is interested in attending.

The following lectures were held during the year:

Professor Catherine Dulac presented the Francis Crick lecture in November 2022 in person and over zoom. The title of the lecture was 'Neurobiology of social and sickness behaviours'. Catherine is Higgins Professor of Molecular and Cellular Biology, the Lee and Ezeleta Professor of Arts and Sciences, and a Howard Hughes Medical Institute Investigator at Harvard University. Her research seeks to improve understanding of how the brain controls instinctive behaviours. In her lecture, she described her laboratory's recent progress in understanding how the brain participates in the positive and negative control of adult-adult social interactions, providing a new framework to understand the regulation of social behaviours in health and disease. She also covered her recent work in uncovering how specific brain circuits are able to direct adaptive changes in behaviour during sickness episodes.

The 2023 Cesar Milstein lecture in January 2023 was held in person at the LMB. Professor Denis Duboule's lecture was on understanding the Hox timer by using mammalian pseudo-embryos. Denis is Professor of Genome Evolution and Development at the College de France, Paris, Professor at the Federal Institute of Technology (EPFL) in Lausanne where he leads the laboratory of Developmental Genomics, and Honorary Professor of Biology at the University of Geneva where he chaired the Department of Genetics and Evolution. Denis' research focus is the regulatory mechanisms behind vertebrate pattern formation in both developmental and evolutionary contexts. In particular, he is a pioneer of research on Hox genes, or 'architect genes', responsible for coordinating body patterning during embryonic development. His identification of Hox genes in mammals has opened up a new field of highly-active research. Over the last 20 years, Denis has implemented an expansive programme aimed at genetically dissecting different aspects of Hox gene biology through both established mouse molecular genetic approaches and by designing new strategies using in vivo chromosome engineering to generate novel genomic rearrangements.

Michael Neuberger Studentship

A donation was made in 2014/15 to help finance a PhD studentship in the name of Michael Neuberger, jointly with Trinity College Cambridge. In October 2021, the second holder of the Michael Neuberger Studentship,

The Max Perutz Fund (a company limited by guarantee)

Andrew Zeller, started his PhD at the LMB in Julian Sale's group. Andrew's project relates to Protein and Nucleic Acid Chemistry Vertebrate mutagenesis and DNA damage tolerance.

The Monoclonal Anti-Bodies (MABs) film

The project is supporting the making of an educational film about monoclonal antibodies, arising from the work of Cesar Milstein's work at the Laboratory of Molecular Biology (LMB) and involving filming of current LMB members as well as archive material. The animation and colouring phase of the MABs film was completed during the year, with some music and sound also being added.

Sangamo Aaron Klug Symposium Fund

Sangamo Therapeutics Inc supported the Aaron Klug Memorial Symposium which was held in May 2022. It was agreed with Sangamo that the unspent funds may be used to further the activities of the Max Perutz Fund.

Other

The Women at LMB symposium (rescheduled from November 2020 due to the covid-19 pandemic) was held in November 2022.

Two summer students were sponsored by the Max Perutz Fund to take up a placement in the LMB, as part of ongoing initiatives to widen participation in science.

Graduate and Postdoctoral networking events were arranged, with funding by the GSA/PAL fund.

The Max Perutz Fund continues to benefit from all proceeds from the sale of Ahead of the Curve, a book showcasing the scientific achievements of pioneering women scientists at the LMB, describing the work they have done within the context of their lives outside the lab.

The LMB again produced themed Christmas cards in 2022; all proceeds from the sale of these were passed to the Max Perutz Fund.

Further information on these initiatives is given in note 14 to the accounts.

Fundraising

No fundraising is carried out on the Max Perutz Fund's behalf by any third party. Information on donating to the fund is included on the Max Perutz Fund's website and donors are also able to donate at LMB open days; no fundraising approaches are made directly to the public. The fund has not received any complaints related to its fundraising but if it ever did receive such a complaint this would be reviewed immediately by the Trustees and treated with the utmost seriousness.

Financial Review

During the year, income for the charity amounted to £332,699 (2022 - £219,385). Donations from individuals totalled £65,651 (2022 - £10,641), donations from corporate donors amounted to £nil (2022 - £53,006) and donations from Trusts amounted to £5,000 (2022 - £nil). Gift aid income of £15,613 (2022 - £560) has been recognised with £15,613 (2022 - £560) included within debtors at the year end.

Resources expended in the year amounted to £179,981 (2022 - £92,764).

The market value of investments rose by £122,928 in the year to 30 September 2023 (2022 – fall of £344,701), with investments now standing at £2,975,034 (2022 - £2,852,106), due to a general increase in investment markets over the course of the year, although significant volatility remains.

The Max Perutz Fund (a company limited by guarantee)

The charity has strong reserves and has not needed to curtail any activities due to the financial impact of the covid-19 pandemic, inflationary factors or more recent current market conditions. The Trustees keep activities under review in light of these issues.

The Trustees have developed an investment policy which reflects the different purposes of the individual funds. Unless the donor expects the donation to be spent in full over a number of years, the priority is to retain the capital value of the donation. For funds which constitute an expendable endowment, the Trustees seek to balance protecting the capital value with maximising income.

Reserves Policy

The Fund has no specific target level of reserves or range of reserves but abides by the following principles. The Fund has no long-term obligations and only makes awards if funds to cover the full value of the award are available. For expendable endowment funds, the Trustees set a reserve which balances the need to sustain the fund and generate income to meet the objectives of the charity. The Max Perutz Fund will not award a grant or a fellowship unless the full value of the commitment is available at the time of the award. Where individual funds are established as an endowment or expendable endowment, then a reserve will be determined by the Trustees with a view to achieving an appropriate annual income level to meet the aims of the fund.

Plans for the coming year

The Trustees will continue to support and encourage scientists in the early stages of their career, through the provision of fellowships, exchange visits, attendance at meetings and the awarding of prizes. It will also continue to foster the aims of the individual restricted funds. As funds permit, the Trustees will consider providing stipends for LMB PhD students who are ineligible for full MRC funding because of their nationality.

Steitz postdoctoral prizes were awarded again in October 2023.

Eileen Southgate prizes for scientific facilities and support staff at the LMB were awarded again in October 2023.

Post-production on the MABs film, 'The Library of All Possible Things' was completed and the final stage payment made in November 2023, bringing the project to completion.

Sales of Ahead of the Curve are continuing. The LMB has produced themed Christmas cards again in 2023 with all proceeds from the sale of these being allocated to the Max Perutz Fund.

The Grigg Fellowship continues to be promoted through the MRC Laboratory of Molecular Biology.

The Max Perutz Fund (a company limited by guarantee)

Trustees' responsibilities in relation to the financial statements

The trustees (who are also directors of the Max Perutz Fund for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Practice).

Company law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP FRS102;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.


The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

In preparing this report the Trustees have taken advantage of the Small Companies exemptions provided by Section 415A of the Companies Act 2006.

Approved by the Trustees on 27/3/24 and signed on their behalf by



Dr Jan Löwe
Chairman of the Max Perutz Fund

The Max Perutz Fund (a company limited by guarantee)

Independent Auditor's Report to the Members of The Max Perutz Fund

Opinion

We have audited the financial statements of The Max Perutz Fund (the 'charitable company') for the year ended 30 September 2023 which comprise the Statement of Financial Activities incorporating Income and Expenditure Account, the Balance sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2023, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial

The Max Perutz Fund (a company limited by guarantee)

statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 10, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above to detect material misstatements in respect of irregularities,

The Max Perutz Fund (a company limited by guarantee)

including fraud. The extent to which our procedures are capable of detecting irregularities including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the charitable company and how it operates and considered the risk of the charitable company not complying with the applicable laws and regulations including fraud in particular those that could have a material impact on the financial statements. This included those regulations directly related to the financial statements. In relation to the charity this included data protection and financial reporting.

The risks were discussed with the audit team and we remained alert to any indications of non-compliance throughout the audit. We carried out specific procedures to address the risks identified. These included the following:


- Management override: We reviewed systems and procedures to identify potential areas of management override risk. In particular, we carried out testing of journal entries and other adjustments for appropriateness.
- Reviewing minutes of Trustee Board meetings and correspondence with the Charity Commission, agreeing the financial statement disclosures to underlying supporting documentation, enquiries of management including those responsible for the key regulations and a review of the risk management processes and procedures in place. We have also reviewed the procedures in place for the reporting of any incidents to the Trustee Board including serious incident reporting of these matters as necessary with the Charity Commission.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members for our audit work, for this report, or for the opinions we have formed.



Shaun Jordan ACA (Senior Statutory Auditor)

For and on behalf of Price Bailey LLP

Chartered Accountants

Statutory Auditors

Tennyson House

Cambridge

CB4 0WZ

United Kingdom

Date: 27 March 2024

The MAX Perutz Fund (a company limited by guarantee)

Statement of Financial Activities (including summary income and expenditure account) for the year ended 30 September 2023

		Unrestricted Funds	Restricted Funds	Expendable Endowment Funds	Total Year 01/10/22 to 30/09/23	Total Year 01/10/21 to 30/09/22
	Note	£	£	£	£	£
Income:						
Donations and legacies						
Donations	3	86,264	0	0	86,264	64,207
Grants Received		0	70,159	0	70,159	0
Investment Income	4	104,251	52,680	19,166	176,097	155,006
Trading income	14	179	0	0	179	172
Total Income		190,694	122,839	19,166	332,699	219,385
Expenditure on:						
Charitable Activities		78,560	101,421	0	179,981	92,761
Trading Activities		0	0	0	0	3
Total Expenditure	5	78,560	101,421	0	179,981	92,764
Net Gains/(Losses) on Investments		72,653	36,863	13,412	122,928	(344,701)
Net (Expenditure) / Income		184,787	58,281	32,578	275,646	(218,080)
Transfers between funds		0	0	0	0	0
Net movement in funds		184,787	58,281	32,578	275,646	(218,080)
Fund Balances brought forward at 01 October 2022		1,878,611	987,466	347,895	3,213,972	3,432,052
Fund Balances carried forward at 30 September 2023		2,063,398	1,045,747	380,473	3,489,618	3,213,972

All of the above results are derived from continuing activities.

The Statement of Financial Activities includes all gains and losses recognised in the year and includes the position of its connected charity, the Sir Gregory Winter Jeantet Prize Fund. See note 15 for further information.

The notes on pages 16 to 24 form part of these financial statements.

The Max Perutz Fund (a company limited by guarantee)


Company Number 6876186

Balance sheet as at 30th September 2023

	Notes	30/09/2023 £	30/09/2022 £
Fixed Assets			
Investments	9	2,975,034	2,852,106
TOTAL FIXED ASSETS		<u>2,975,034</u>	<u>2,852,106</u>
Current Assets			
Debtors: amounts falling due within one year	10	18,108	560
Cash at bank and in hand		515,277	382,021
TOTAL CURRENT ASSETS		<u>533,385</u>	<u>382,581</u>
Creditors: amounts falling due within one year	11	(18,801)	(20,715)
Net current assets		<u>514,584</u>	<u>361,866</u>
Net Assets		<u><u>3,489,618</u></u>	<u><u>3,213,972</u></u>
Funds of the charity			
Unrestricted Funds			
General Funds		1,181,833	1,020,607
Designated Funds		881,565	858,005
		<u>2,063,398</u>	<u>1,878,612</u>
Restricted Funds			
Restricted Funds		1,045,747	987,466
Expendable Endowment Funds		380,473	347,894
		<u>1,426,220</u>	<u>1,335,360</u>
Total Funds	12	<u><u>3,489,618</u></u>	<u><u>3,213,972</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 27/3/24 and signed on their behalf by



Dr Jan Löwe
Chairman of the Max Perutz Fund

The notes on pages 16 to 24 form part of these financial statements.

The Max Perutz Fund (a company limited by guarantee)

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

1.1 Basis of preparation of financial statements

These accounts have been prepared in accordance with Financial Reporting Standard 102 – 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' (FRS 102) and with the Statement of Recommended Practice Accounting and Reporting by Charities' FRS 102, (effective 1 January 2019) together with the reporting requirements of the Companies Act 2006 and the Charities Act 2011.

The Charity constitutes a public benefit entity as defined by FRS 102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The financial statements are presented in sterling, which is the functional currency of the charity and are rounded to the nearest pound.

The Charity is registered in England and Wales. The address of the Charity's registered office is shown on page 2.

1.2 Cashflow Exemption

The company, being a company of small size within the meaning of the Companies Act 2006, has used the exemption provided by the early adoption of the SORP Bulletin issued in February 2016 under which it is not required to include a cashflow statement as part of the financial statements.

1.3 Going Concern

The trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in the preparation of the financial statements.

1.4 Legal Status

There is no share capital as the company is limited by guarantee. Each member has guaranteed an amount, not exceeding £10, towards the company's liabilities in the event of a winding up.

1.5 Fund Accounting

General Funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by the donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Expendable endowments managed by the Max Perutz Fund are Expendable Endowments and are to be held by the charity for a lengthy but not permanent period. The Expendable Endowments are the result of donations which will be spent in accordance with the objectives of the charity, and any income arising from the investment of the Endowments are attributed as additions to the Endowments. Any investment management charges and legal advice relating to the Endowments are charged against the funds.

1.6 Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

For legacies, entitlement is taken on a case by case basis as the earlier of the date on which the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. If the legacy is in the form of an asset other than cash or an asset listed on a recognised stock exchange, recognition is subject to the value of the asset being able to be reliably measured and title to the asset has passed to the charity. Where legacies have been notified or the charity is aware of the granting of probate, and the criteria for income recognition has not been met, then the legacy is treated as a contingent asset and disclosed if material.

No amounts are included in the financial statements for services donated by volunteers.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.7 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of the resources.

1.8 Fixed assets investments

Quoted investments are valued at the balance sheet date at market value. Revaluation gains or losses are recognised in the statement of financial activities, and attributed to the fund for which the investments are held.

1.9 Cash at Bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.10 Creditors

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors are normally recognised at their settlement amount after allowing for any trade discounts due.

1.11 Financial Instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, which, in the case of the charity is at cost for creditors and debtors and market value for investments.

2 Judgements and key sources of estimation uncertainty

In the application of the Charity's accounting policies, which are described in note 1, the Trustees are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates' associated assumptions are based on historical experience and other factors considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The Trustees do not consider there are any critical accounting judgements or key sources of estimation uncertainty requiring disclosure.

The Max Perutz Fund (a company limited by guarantee)

3 Donations and legacies

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Individuals	65,651	10,641
Gift Aid	15,613	560
Corporate Donors	0	53,006
Trusts	5,000	0
	<u>86,264</u>	<u>64,207</u>

Of the above donations, £nil related to restricted funds and the remainder to unrestricted funds;
in 2022 £35,506 related to restricted funds and the remainder to unrestricted funds.

4 Investment Income

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Interest Receivable	426	8
Dividends received from Investments	175,671	154,998
	<u>176,097</u>	<u>155,006</u>

Investment income for 2023 was £176,097 (2022 - £155,006) of which £104,251 (2022 - £90,559) was attributable to
unrestricted funds, £52,680 (2022 - £47,657) was attributable to restricted funds and £19,166 (2022 - £16,790) was
attributable to restricted expendable endowments.

5a Analysis of Expenditure - Current Year

	Activites Undertaken Directly £	Grant funding of activities £	Support Costs (Note 6) £	Total Funds £
Promotion and advancement of education and research	47,924	123,640	8,417	179,981
Trading activities	0	0	0	0
	<u>47,924</u>	<u>123,640</u>	<u>8,417</u>	<u>179,981</u>

5b Analysis of Expenditure - Prior Year

	Activites Undertaken Directly £	Grant funding of activities £	Support Costs (Note 6) £	Total Funds £
Promotion and advancement of education and research	44,499	40,317	7,945	92,761
Trading activities	3	0	0	3
	<u>84,819</u>	<u>40,317</u>	<u>7,945</u>	<u>92,764</u>

Expenditure on charitable activities includes £25,429 (2022 - £23,866) spent from unrestricted funds, £53,131
(2022 - £47,042) spent from designated funds, £101,421 (2022 - £21,856) spent from restricted funds and £ Nil (2022 -
£ Nil) from restricted expendable endowment funds.

During the year the charity made three grants to institutions totaling £123,640 (2022 - one, £40,317). All grants were payable
to the Medical Research Council Laboratory of Molecular Biology (LMB). Included within the total was £70,159 relating to
a grant to support a project of Ben Ryskeldi-Falcon (2022 - £ Nil), further information on which is detailed on page 5.

No expenditure was incurred on raising funds in 2023 (2022 - £ Nil).

The Max Perutz Fund (a company limited by guarantee)

6 Analysis of Support Costs

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Professional Fees	1,680	1,621
Bank Fees	160	168
Trustee Indemnity Insurance	264	967
Accountancy Services	13	13
Governance Costs (See note 7)	6,300	5,176
	<u>8,417</u>	<u>7,945</u>

7 Analysis of Governance Costs

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Audit Fees	<u>6,300</u>	<u>5,176</u>

8 Trustees' remuneration

The trustees received no emoluments or reimbursed expenses during the year (2022 - £Nil).

During the year, insurance was purchased to indemnify the Trustees against default on their part. The cost of the insurance amounted to £264 (2022 - £967).

9 Fixed asset investments

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Market value as at 1st October	2,852,106	2,896,807
Additions	0	300,000
Disposal Proceeds	0	0
Net investments gains / (losses)	122,928	(344,701)
Market value as at 30th September	<u>2,975,034</u>	<u>2,852,106</u>
Historical cost as at 30th September	<u>2,590,854</u>	<u>2,590,854</u>
UK listed investments are represented by:		
Investment trusts and unit trusts	<u>2,975,034</u>	<u>2,852,106</u>
	<u>2,975,034</u>	<u>2,852,106</u>

The Max Perutz Fund (a company limited by guarantee)

10 Debtors: amounts falling due within one year

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Gift aid accrued income	15,613	560
Prepayments	2,495	0
	<u>18,108</u>	<u>560</u>

11 Creditors: amounts falling due within one year

	Total for the Year 01/10/2022 to 30/09/2023 £	Total for the Year 01/10/2021 to 30/09/2022 £
Accruals	<u>18,801</u>	<u>20,715</u>

12a Statement of Funds - current year

	At 01/10/2022 £	Income £	Expenditure £	Transfers In/Out £	Investment Gains/ (Losses) £	At 30/09/2023 £
General Fund	1,020,607	144,995	(25,429)	0	41,660	1,181,833
Designated Funds						
Perutz Fund	312,110	18,599	(1,500)	0	12,029	341,238
Milstein Fund	522,649	26,081	(49,245)	0	18,251	517,735
AstraZeneca						
Lecture Series	20,882	1,019	(2,386)	0	713	20,228
Michael						
Neuberger						
Studentship	2,364	0	0	0	0	2,364
Total	<u>1,878,611</u>	<u>190,694</u>	<u>(78,560)</u>	<u>0</u>	<u>72,653</u>	<u>2,063,398</u>
Unrestricted funds						
Restricted funds						
Steitz (formerly Brenner)						
Postdoc Prize	27,673	327	(21,733)	0	229	6,496
Sangamo Aaron Klug						
Symposium	3,588	0	(3,588)	0	0	0
GSA/PAL Fund	2,192	10	(2,014)	0	7	195
Fidelity Bermuda	0	70,159	(70,159)	0	0	0
Jeantet						
Ramakrishnan	343,204	18,692	(3,927)	0	13,079	371,048
Jeantet Winter	610,809	33,651	0	0	23,548	668,008
	<u>987,466</u>	<u>122,839</u>	<u>(101,421)</u>	<u>0</u>	<u>36,863</u>	<u>1,045,747</u>
Expendable						
Endowments						
Agouron	240,758	13,264	0	0	9,282	263,304
Grigg Fund	107,137	5,902	0	0	4,130	117,169
	<u>347,895</u>	<u>19,166</u>	<u>0</u>	<u>0</u>	<u>13,412</u>	<u>380,473</u>
Total						
restricted funds	<u>1,335,360</u>	<u>142,005</u>	<u>(101,421)</u>	<u>0</u>	<u>50,275</u>	<u>1,426,220</u>
Total funds	<u>3,213,972</u>	<u>332,699</u>	<u>(179,981)</u>	<u>0</u>	<u>122,928</u>	<u>3,489,618</u>

The Max Perutz Fund (a company limited by guarantee)

12b Statement of Funds - prior year

	At 01/10/2021 £	Income £	Expenditure £	Transfers In/Out £	Investment Gains/ (Losses) £	At 30/09/2022 £
General Fund	1,096,930	57,084	(23,866)	0	(109,541)	1,020,607
Designated Funds						
Perutz Fund	331,290	15,819	(1,500)	0	(33,499)	312,110
Milstein Fund	597,302	25,224	(43,781)	0	(56,096)	522,649
AstraZeneca Lecture Series	3,876	21,008	(1,761)	0	(2,241)	20,882
Michael Neuberger Studentship	2,067	297	0	0	0	2,364
Total						
Unrestricted funds	<u>2,031,465</u>	<u>119,432</u>	<u>(70,908)</u>	<u>0</u>	<u>(201,377)</u>	<u>1,878,611</u>
Restricted funds						
Steitz (formerly Brenner)						
Postdoc Prize	11,138	34,341	(14,836)	0	(2,970)	27,673
Sangamo Aaron Klug Symposium	10,497	173	(6,697)	0	(385)	3,588
GSA/PAL Fund	0	2,606	(178)	0	(236)	2,192
Jeanter						
Ramakrishnan	363,621	16,564	(145)	0	(36,836)	343,204
Jeanter Winter	646,888	29,479	0	0	(65,558)	610,809
	<u>1,032,144</u>	<u>83,163</u>	<u>(21,856)</u>	<u>0</u>	<u>(105,985)</u>	<u>987,466</u>
Expendable Endowments						
Agouron	254,979	11,619	0	0	(25,840)	240,758
Grigg Fund	113,464	5,171	0	0	(11,499)	107,137
	<u>368,443</u>	<u>16,790</u>	<u>0</u>	<u>0</u>	<u>(37,339)</u>	<u>347,895</u>
Total restricted funds	<u>1,400,588</u>	<u>99,953</u>	<u>(21,856)</u>	<u>0</u>	<u>(143,324)</u>	<u>1,335,360</u>
Total funds	<u>3,432,052</u>	<u>219,385</u>	<u>(92,764)</u>	<u>0</u>	<u>(344,701)</u>	<u>3,213,972</u>

Purposes of Designated Funds

The **Max Perutz Fund** is used to fund prizes for young scientists and other approved purposes including for young scientists to attend Scientific Conferences of vocational interest to their studies.

The **Milstein Fund** funds a studentship or a fellowship to enable a young scientist from South America to undertake research at the LMB.

AstraZeneca Lecture Series funds a series of lectures given by leading national and international researchers in their biological and medical fields to an interested and open public audience.

Michael Neuberger Studentship was set up as a memorial to Dr Michael Neuberger who died in October 2013 to fund the training of PhD students in fundamental biological and medical research. Dr Neuberger worked as biochemist and immunologist at the Laboratory of Molecular Biology Cambridge, where he was also Deputy Director. The main fund is hosted by Trinity College Cambridge.

Purposes of Restricted Funds

The **Steitz (formerly Brenner) LMB Postdoc Prize** is used to fund prizes for outstanding research by postdocs or investigators at the LMB.

The **Ramakrishnan Jeantet Fund** is a donation from the Louis Jeantet Foundation in respect of an award to Dr Venkatraman (Venki) Ramakrishnan for the Louis Jeantet Prize in 2017. Dr Ramakrishnan's work on the atomic structure and workings of the ribosome, which is responsible for protein synthesis within cells, has the potential to underpin the development of new drugs to help fight antibiotic resistance.

The **Winter Jeantet Fund** is a donation from the Louis Jeantet Foundation in respect of an award made to Dr Greg Winter originally in 1989, and managed until May 2012 within the private charitable funds of the MRC, until it was mutually agreed that the residue of the funds should be passed to the Max Perutz Fund. The fund is supporting work on a new technology that Dr Winter invented involving bicyclic peptides. The technology is very similar to that used to isolate human antibodies from the bacteria, with many of the same advantages. However the bicycles are much smaller and be chemically synthesised with ease. This technology potentially offers new opportunities to make novel therapeutics, but it is first necessary to explore the properties of the bicycles and optimise methods to make them. This fund relates to the funds of The Sir Gregory Jeantet Prize Fund, a charity linked to The Max Perutz Fund by the Charity Commission. See note 15 for more information.

The **Sangamo Aaron Klug Symposium Fund** is a donation from Sangamo Therapeutics Inc which funded the Aaron Klug Memorial Symposium; surplus funds are being used for academic support.

The **Graduate Scientist/Postdoctoral Researcher Fund ('GSA/PAL fund')** was created in 2022 and is used to fund networking activities for graduate students and postdoctoral researchers.

The **Fidelity Bermuda Foundation** awarded a grant to support a project of Ben Ryskeldi-Falcon at the LMB, entitled 'In situ structural cell biology of tau and TDP-43 filaments in the human brain'. The first year of funding was received and remitted to the LMB during the year.

Purposes of Expendable Endowments

The **Agouron Fund** is a donation given by Agouron to assist in the long term funding of Dr Venki Ramakrishnan's research.

The **Grigg Fellowship Fund** promotes closer links between the Garvan Institute of Medical Research in Australia and the LMB.

The Max Perutz Fund (a company limited by guarantee)

13a Analysis of Net Assets between Funds - current year

	General Funds £	Designated Funds £	Restricted Funds £	Expendable Endowments Funds £	Total Funds £
Investments	1,007,558	751,568	891,539	324,368	2,975,034
Current Assets	184,061	139,012	154,207	56,105	533,385
Current Liabilities	(9,786)	(9,015)	0	0	(18,801)
Net Assets at					
30 September 2023	<u>1,181,833</u>	<u>881,565</u>	<u>1,045,747</u>	<u>380,473</u>	<u>3,489,618</u>

13b Analysis of Net Assets between Funds - prior year

	General Funds £	Designated Funds £	Restricted Funds £	Expendable Endowments Funds £	Total Funds £
Investments	905,695	761,401	876,286	308,724	2,852,106
Current Assets	127,229	104,824	111,358	39,170	382,581
Current Liabilities	(12,317)	(8,220)	(178)	0	(20,715)
Net Assets at					
30 September 2022	<u>1,020,607</u>	<u>858,005</u>	<u>987,466</u>	<u>347,894</u>	<u>3,213,972</u>

14 Related parties and key management personnel

The charity had no employees during the year (2022 - Nil) and as such there was no key management personnel remuneration (2022 - Nil).

Prizes were made to individual students, postdoctoral staff and technicians employed by the Medical Research Council Laboratory of Molecular Biology (LMB). The total value of these awards was £21,014 (2022 - £23,355).

Grants of £123,640 were made to the LMB for fellowships, summer studentships and the support of a research project of Ben Ryskeldi-Falcon - further details are shown in note 5b (2022- £40,317).

The Medical Research Council Laboratory of Molecular Biology (LMB) funded the preparation of a book, 'Ahead of the Curve', to celebrate the contribution of women scientists at the LMB. The book was obtainable from the Max Perutz Fund on payment of a suggested donation at least sufficient to cover the cost of the book and postage. The costs paid for by the LMB for books distributed totalled £1,179 (2022 - £412).

The LMB also paid for the production of the Christmas cards sold by the Max Perutz Fund, generating revenue of £179 for the Fund (2022 - £172). The costs of the cards sold and funded by the LMB was £159 (2022 - £155).

There were no other related party transactions requiring disclosure during the year (2022 - none).

Connected charities

Since 6 January 2021 the Sir Gregory Winter Jeantet Prize Fund has been linked by the Charity Commission to the Max Perutz Fund. The details of the linked charity are as follows:

Charity registration no: 1129597-1

Governing document: User trusts

Charitable objective: see note 12 on page 23.

The Fund's assets were transferred to the Max Perutz Fund in May 2012 and classified as restricted funds. The movements on the Fund are as disclosed in note 12. The only income for the Fund in the year was dividends received; the Fund had no expenditure in the year.